pharmaceuticals

A new HHS rule would require Medicare and Medicaid to cover drugs like Wegovy or Zepbound for a large segment of Americans. But it’s unclear if it will will have support of the Trump administration.

The state sued the FDA over what it said was a “reckless delay” in approving its drug importation plan. Nearly a year after the federal officials gave the green light, the program has yet to begin.

The guidelines took years to finalize, but while regulators were drafting them, a new trend emerged: online pharmaceutical influencers with little government oversight.

Criticism of prescription drug middlemen has intensified recently in the wake of a federal agency’s actions and legislative reform attempts.

A woman ended up stranded in the hospital because CVS stopped providing the IV nutrition she needs to survive at home. Without it, she’d starve.

The Big Three pharmacy benefit managers say they return nearly all the rebates they get from drugmakers to the employers and insurers who hire them. But most employers seem to doubt that.

The pharmaceutical industry has invented a new art form: finding ways to make their wares seem like joyous must-have treatments, while often minimizing lackluster efficacy and risks.

The FDA considers plants that have gone more than five years without an inspection to be a significant risk. Officials say the work has been hampered by difficulties recruiting and retaining inspectors.

The school district is self-insured, meaning it foots the bill for the health care costs of employees. As many as 3,500 employees may be affected by insulin price increases over the past 20 years.

As Congress pushes for Medicare to cover payment for anti-obesity drugs, Denmark — home of Ozempic maker Novo Nordisk — has limited coverage of the drug after cost overruns “emptied all the money boxes in the entire public health system.”